Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02447250 · ClinicalTrials.gov registry record · Phase 4
Preterm Infant Inhaled Albuterol Dosing
A Phase 4 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
NCT02447250 is a Phase 4 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 14 participants.
The verdict
NCT02447250, a Phase 4 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to help determine the best dose of inhaled albuterol sulfate in premature babies at risk of developing bronchopulmonary dysplasia (BPD). BPD is the chronic lung disease of prematurity and is associated with increased morbidity and mortality, longer hospital stays, and increased healthcare utilization. Albuterol is an inhaled medication frequently used in premature infants with chronic lung disease and in people with asthma. It is believed to be safe, but the optimal dose for infants is not clear. The investigators hypothesize that albuterol may help a subset of premature infants with lung disease, but they need to determine the best dose prior to doing research about how effective it is for chronic lung disease/BPD. Response to each of three doses of albuterol will be measure using pulmonary function tests.
Interventions
- DRUG Varied albuterol dose response
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2013-10-24 |
| Est. Completion | 2014-12-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02447250
The ClinicalTrials.gov registry entry for NCT02447250 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Varied albuterol dose response is the first listed.
NCT02447250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02447250 about?
NCT02447250 is a clinical study titled "Preterm Infant Inhaled Albuterol Dosing". The purpose of this study is to help determine the best dose of inhaled albuterol sulfate in premature babies at risk of developing bronchopulmonary dysplasia (BPD). BPD is the chronic lung disease of prematurity and is associated with increased morbidity and mortality, longer hospital stays, and in...
What is the current status of trial NCT02447250?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2013-10-24. Estimated completion is 2014-12-30.
What interventions are being tested in trial NCT02447250?
The interventions under investigation include: Varied albuterol dose response (DRUG).
Who is sponsoring clinical trial NCT02447250?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.